Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform, announced today the appointment of Dr. Elisabeth Lackner to its Supervisory Board. Dr. Lackner’s appointment adds broad biopharmaceutical industry expertise to Eleva’s board including insights into clinical development, contract research and manufacturing.

“We are proud to have attracted in Elisabeth Lackner a highly experienced and well-respected leader with more than 20 years of experience in the healthcare industry,” commented Bj?rn Cochlovius Ph.D., Chief Executive Officer of Eleva. “I look forward to working with Elisabeth and our entire Supervisory Board as Eleva continues on its path as an emerging drug development organization unlocking unique product opportunities based on our innovative technology platform.”

Commenting on her appointment, Dr. Elisabeth Lackner added: “Eleva is positioned at a valuable intersection of enabling technologies, proprietary and partnered drug development, and innovative manufacturing strategies. I look forward to contributing my expertise and network to support the company in achieving its upcoming milestones and long-term goals and gain further traction for its technologies and product candidates.”

Dr. Elisabeth Lackner currently serves as Chief Executive Officer (CEO) at CRS Clinical Research Services, a leading contract research organization and multi-indication specialist operating a network of study sites with clinical trials spanning from First-in-Human to Proof-of-Concept studies. Prior to that, she held the position of Chief Scientific Officer and member of the operating board at Element Materials Technology, a global leader in testing, inspection, and certification services. Earlier in her career, she led the merger of ABF Pharmaceutical Services and GBA Group Pharma, serving post-merger as the CEO of the GBA’s Pharma Division. In addition to her industry career, Dr. Lackner held roles as Managing Director of Vineta, a Life Sciences-focused family office, as well as several board roles. Dr. Lackner holds a PhD in Pharmacy from the University of Vienna.

Dr. Elisabeth Lackner

About Eleva

Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough manufacturing platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.